Pharmacological treatment of anxiety disorders: Current treatments and future directions

Journal of Anxiety Disorders

Volumn 26, Issue 8, 2012, Pages 833-843

  Farach, Frank J ^a   Pruitt, Larry D ^a   Jun, Janie J ^a   Jerud, Alissa B ^a   Zoellner, Lori A ^a   Roy Byrne, Peter P ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Antidepressants; Anxiety disorders; Memory consolidation; Pharmacotherapy; Psychedelics

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; AZAPIRONE; BENZODIAZEPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; ESZOPICLONE; GABAPENTIN; LITHIUM; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; NEUROKININ 1 RECEPTOR ANTAGONIST; NEUROLEPTIC AGENT; NEUROPEPTIDE; NEUROPEPTIDE Y; NEUROPEPTIDE Y RECEPTOR AGONIST; PLACEBO; PREGABALIN; QUETIAPINE; RISPERIDONE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN RECEPTOR AFFECTING AGENT; SEROTONIN UPTAKE INHIBITOR; THYROID HORMONE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASOPRESSIN; VENLAFAXINE;

ANORGASMIA; ANXIETY; ANXIETY DISORDER; COGNITIVE DEFECT; DEPRESSION; DIARRHEA; DRUG DEPENDENCE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; EATING DISORDER; ERECTILE DYSFUNCTION; EVIDENCE BASED PRACTICE; FEAR; GENERALIZED ANXIETY DISORDER; HEADACHE; HUMAN; INSOMNIA; LEUKOPENIA; LIVER TOXICITY; MAJOR DEPRESSION; MEMORY; NAUSEA; NERVOUSNESS; NONHUMAN; PANIC; POSTTRAUMATIC STRESS DISORDER; PREMENSTRUAL DYSPHORIC DISORDER; PSYCHOMOTOR DISORDER; REBOUND; RESTLESSNESS; REVIEW; SEIZURE; SEXUAL BEHAVIOR; SEXUAL DYSFUNCTION; SEXUAL SATISFACTION; SIDE EFFECT; SOMNOLENCE; TREATMENT DURATION; WEIGHT GAIN;

ANTI-ANXIETY AGENTS; ANXIETY DISORDERS; DRUG THERAPY; HUMANS; TREATMENT OUTCOME;

EID: 84866646660     PISSN: 08876185     EISSN: 18737897     Source Type: Journal    
DOI: 10.1016/j.janxdis.2012.07.009     Document Type: Review

References (152)

1. Aikens J.E., Nease D.E., Nau D.P., Klinkman M.S., Schwenk T.L. Adherence to maintenance-phase antidepressant medication as a function of patient beliefs about medication. Annals of Family Medicine 2005, 3:23-30. 10.1370/afm.238.
2. Aranda-Michel J., Koehler A., Bejarano P.A., Poulos J.E., Luxon B.A., Mobin Khan C., et al. Nefazodone-induced liver failure:report of three cases. Annals of Internal Medicine 1999, 130:285-288.
3. Arborelius L., Owens M.J., Plotsky P.M., Nemeroff C.B. The role of corticotropin-releasing factor in depression and anxiety disorders. The Journal of Endocrinology 1999, 160:1-12.
4. Bakish D., Hooper C.L., West D.L., Miller C., Blanchard A., Bashir F. Moclobemide and specific serotonin re-uptake inhibitor combination treatment of resistant anxiety and depressive disorders. Human Psychopharmacology: Clinical and Experimental 1995, 10:105-109. 10.1002/hup.470100205.
5. Bandelow B., Seidler-Brandler U., Becker A., Wedekind D., Rüther E. Meta-analysis of randomized controlled comparisons of psychopharmacological and psychological treatments for anxiety disorders. World Journal of Biological Psychiatry 2007, 8:175-187. 10.1080/15622970601110273.
6. Barlow D.H. Psychological treatments. American Psychologist 2004, 59:869-878.
7. Becker M.E., Hertzberg M.A., Moore S.D., Dennis M.F., Bukenya D.S., Beckham J.C. A placebo-controlled trial of bupropion SR in the treatment of chronic posttraumatic stress disorder. Journal of Clinical Psychopharmacology 2007, 27:193-197. 10.1097/JCP.0b013e318032eaed.
8. Belzung C., Yalcin I., Griebel G., Surget A., Leman S. Neuropeptides in psychiatric diseases:an overview with a particular focus on depression and anxiety disorders. CNS and Neurological Disorders Drug Targets 2006, 5:135-145.
9. Bergamaschi M.M., Queiroz R.H.C., Chagas M.H.N., de Oliveira D.C.G., De Martinis B.S., Kapczinski F., et al. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients. Neuropsychopharmacology 2011, 36:1219-1226. 10.1038/npp.2011.6.
10. Bloch M.H., McGuire J., Landeros-Weisenberger A., Leckman J.F., Pittenger C. Meta-analysis of the dose-response relationship of SSRI in obsessive-compulsive disorder. Molecular Psychiatry 2009, 15:850-855.
11. Bouso J.C., Doblin R., Farré M., Alcázar M.A., Gómez-Jarabo G. MDMA-assisted psychotherapy using low doses in a small sample of women with chronic posttraumatic stress disorder. Journal of Psychoactive Drugs 2008, 40:225-236.
12. Bouton M.E. Context, ambiguity, and unlearning:sources of relapse after behavioral extinction. Biological Psychiatry 2002, 2002:976-986.
13. Cahill L., McGaugh J.L. A novel demonstration of enhanced memory associated with emotional arousal. Consciousness and Cognition 1995, 4:410-421. 10.1006/ccog.1995.1048.
14. Cain C.K., Blouin A.M., Barad M. Adrenergic transmission facilitates extinction of conditional fear in mice. Learning and Memory 2004, 11:179-187. 10.1101/lm.71504.
15. Cami J., Farré M., Mas M., Roset P.N., Poudevida S., Mas A., et al. Human pharmacology of 3,4-methylenedioxymethamphetamine (" ecstasy"): psychomotor performance and subjective effects. Journal of Clinical Psychopharmacology 2000, 20:455-466.
16. Charney D.S., Heninger G.R., Breier A. Noradrenergic function in panic anxiety:effects of yohimbine in healthy subjects and patients with agoraphobia and panic disorder. Archives of General Psychiatry 1984, 41:751-763. 10.1001/archpsyc.1984.01790190025003.
17. Christiana J., Gilman S., Guardino M., Mickelson K., Morselli P., Olfson M., et al. Duration between onset and time of obtaining initial treatment among people with anxiety and mood disorders:an international survey of members of mental health patient advocate groups. Psychological Medicine 2000, 30:693-703.
18. Colado M.I., Williams J.L., Green A.R. The hyperthermic and neurotoxic effects of " Ecstasy" (MDMA) and 3,4 methylenedioxyamphetamine (MDA) in the Dark Agouti (DA) rat, a model of the CYP2D6 poor metabolizer phenotype. British Journal of Pharmacology 1995, 115:1281-1289.
19. Coric V., Taskiran S., Pittenger C., Wasylink S., Mathalon D.H., Valentine G., et al. Riluzole augmentation in treatment-resistant obsessive-compulsive disorder:an open-label trial. Biological Psychiatry 2005, 58:424-428. 10.1016/j.biopsych.2005.04.043.
20. Craske M.G., Kircanski K., Zelikowsky M., Mystkowski J., Chowdhury N., Baker A. Optimizing inhibitory learning during exposure therapy. Behaviour Research and Therapy 2008, 46:5-27. 10.1016/j.brat.2007.10.003.
21. Crippa J.A.de.S., Zuardi A.W., Garrido G.E.J., Wichert-Ana L., Guarnieri R., et al. Effects of cannabidiol (CBD) on regional cerebral blood flow. Neuropsychopharmacology 2004, 29:417-426. 10.1038/sj.npp.1300340.
22. Crippa J.A.de.S., Zuardi A.W., Hallak J.E.C. Uso terapêutico dos canabinoides em psiquiatria. Revista Brasileira de Psiquiatria 2010, 32:556-566. 10.1590/S1516-44462010000500009.
23. Crippa J.A.de.S., Derenusson G.N., Ferrari T.B., Wichert-Ana L., Duran F.L., et al. Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder:a preliminary report. Journal of Psychopharmacology 2011, 25:121-130. 10.1177/0269881110379283.
24. Davidson J.R.T. Seizures and bupropion:a review. Journal of Clinical Psychiatry 1989, 50:256-261.
25. Davidson J.R.T., DuPont R.L., Hedges D., Haskins J.T. Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder. Journal of Clinical Psychiatry 1999, 60:528-535.
26. Davidson J.R.T., Weisler R.H., Butterfield M.I., Casat C.D., Connor K.M., Barnett S., et al. Mirtazapine vs. placebo in posttraumatic stress disorder:a pilot trial. Biological Psychiatry 2003, 53:188-191.
27. de Kleine R.A., Hendriks G.-J., Kusters W.J.C., Broekman T.G., van Minnen A. A randomized placebo-controlled trial of d-cycloserine to enhance exposure therapy for posttraumatic stress disorder. Biological Psychiatry 2012, 71:962-968. 10.1016/j.biopsych.2012.02.033.
28. de Quervain D.J.-F., Margraf J. Glucocorticoids for the treatment of post-traumatic stress disorder and phobias:a novel therapeutic approach. European Journal of Pharmacology 2008, 583:365-371. 10.1016/j.ejphar.2007.11.068.
29. de Quervain D.J.-F., Aerni A., Schelling G., Roozendaal B. Glucocorticoids and the regulation of memory in health and disease. Frontiers in Neuroendocrinology 2009, 30:358-370. 10.1016/j.yfrne.2009.03.002.
30. de Quervain D.J.-F., Bentz D., Michael T., Bolt O.C., Wiederhold B.K., Margraf J., et al. Glucocorticoids enhance extinction-based psychotherapy. Proceedings of the National Academy of Sciences of the United States of America 2011, 108:6621-6625. 10.1073/pnas.1018214108.
31. Debiec J., Bush D.E.A., LeDoux J.E. Noradrenergic enhancement of reconsolidation in the amygdala impairs extinction of conditioned fear in rats - a possible mechanism for the persistence of traumatic memories in PTSD. Depression and Anxiety 2011, 28:186-193. 10.1002/da.20803.
32. Depping A.M., Komossa K., Kissling W., Leucht S. Second-generation antipsychotics for anxiety disorders. Cochrane database of systematic reviews 2010, John Wiley & Sons, Ltd., Chichester, UK, Retrieved from. http://doi.wiley.com/10.1002/14651858.CD008120.pub2, The Cochrane Collaboration, S. Leucht (Eds.).
33. Doblin R. A clinical plan for MDMA (Ecstasy) in the treatment of posttraumatic stress disorder (PTSD): partnering with the FDA. Journal of Psychoactive Drugs 2002, 34:185-194.
34. Feltner D.E., Wittchen H.-U., Kavoussi R., Brock J., Baldinetti F., Pande A.C. Long-term efficacy of pregabalin in generalized anxiety disorder. International Clinical Psychopharmacology 2008, 23:18-28. 10.1097/YIC.0b013e3282f0f0d7.
35. Feltner D.E., Liu-Dumaw M., Schweizer E., Bielski R. Efficacy of pregabalin in generalized social anxiety disorder. International Clinical Psychopharmacology 2011, 26:213-220. 10.1097/YIC.0b013e32834519bd.
36. Food and Drug Administration FDA drug safety communication:serious CNS reactions possible when methylene blue is given to patients taking certain psychiatric medications 2011, July, FDA, Retrieved from: http://www.fda.gov/Drugs/DrugSafety/ucm263190.htm.
37. Fournier J.C., DeRubeis R.J., Hollon S.D., Dimidjian S., Amsterdam J.D., Shelton R.C., et al. Antidepressant drug effects and depression severity. Journal of the American Medical Association 2010, 303:47-53. 10.1001/jama.2009.1943.
38. Furieri F.A., Nakamura-Palacios E.M. Gabapentin reduces alcohol consumption and craving:a randomized, double-blind, placebo-controlled trial. The Journal of Clinical Psychiatry 2007, 68:1691-1700.
39. Fusar-Poli P., Allen P., Bhattacharyya S., Crippa J.A.de.S., Mechelli A., et al. Modulation of effective connectivity during emotional processing by Δ9-tetrahydrocannabinol and cannabidiol. The International Journal of Neuropsychopharmacology 2009, 13:421-432. 10.1017/S1461145709990617.
40. Gabriele A., Packard M.G. d-Cycloserine enhances memory consolidation of hippocampus-dependent latent extinction. Learning and Memory 2007, 14:468-471. 10.1101/lm.528007.
41. Gibbons R.D., Hur K., Brown C.H., Davis J.M., Mann J.J. Benefits from antidepressants:synthesis of 6-week patient-level outcomes from double-blind placebo-controlled randomized trials of fluoxetine and venlafaxine. Archives of General Psychiatry 2012, 572-579.
42. Goddard A.W., Brouette T., Almai A., Jetty P., Woods S.W., Charney D. Early coadministration of clonazepam with sertraline for panic disorder. Archives of General Psychiatry 2001, 58:681-686. 10.1001/archpsyc.58.7.681.
43. Gonzalez-Lima F., Bruchey A.K. Extinction memory improvement by the metabolic enhancer methylene blue. Learning and Memory 2004, 11:633-640. 10.1101/lm.82404.
44. Griebel G., Simiand J., Serradeil-Le Gal C., Wagnon J., Pascal M., Scatton B., et al. Anxiolytic-, antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR, 149415, suggest an innovative approach for the treatment of stress-related disorders. Proceedings of the National Academy of Sciences of the United States of America 2002, 99:6370-6375. 10.1073/pnas.092012099.
45. Grilo C.M., Money R., Barlow D.H., Goddard A.W., Gorman J.M., Hofmann S.G., et al. Pretreatment patient factors predicting attrition from a multicenter randomized controlled treatment study for panic disorder. Comprehensive Psychiatry 1998, 39:323-332. 10.1016/S0010-440X(98)90043-8.
46. Gross C., Zhuang X., Stark K., Ramboz S., Oosting R., Kirby L., et al. Serotonin 1A receptor acts during development to establish normal anxiety-like behaviour in the adult. Nature 2002, 416:396-400. 10.1038/416396a.
47. Guastella A.J., Richardson R., Lovibond P.F., Rapee R.M., Gaston J.E., Mitchell P., et al. A randomized controlled trial of d-cycloserine enhancement of exposure therapy for social anxiety disorder. Biological Psychiatry 2008, 63:544-549. 10.1016/j.biopsych.2007.11.011.
48. Gutman D.A., Owens M.J., Skelton K.H., Thrivikraman K.V., Nemeroff C.B. The corticotropin-releasing factor 1 receptor antagonist R121919 attenuates the behavioral and endocrine responses to stress. Journal of Pharmacology and Experimental Therapeutics 2003, 304:874-880. 10.1124/jpet.102.042788.
49. Harris D.S., Baggott M., Mendelson J.H., Mendelson J.E., Jones R.T. Subjective and hormonal effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology 2002, 162:396-405. 10.1007/s00213-002-1131-1.
50. Hatzidimitriou G., McCann U.D., Ricaurte G.A. Altered serotonin innervation patterns in the forebrain of monkeys treated with (+/-)3,4-methylenedioxymethamphetamine seven years previously:factors influencing abnormal recovery. The Journal of Neuroscience 1999, 19:5096-5107.
51. Heilig M. The NPY system in stress, anxiety and depression. Neuropeptides 2004, 38:213-224. 10.1016/j.npep.2004.05.002.
52. Heilig M., McLeod S., Brot M., Heinrichs S.C., Menzaghi F., Koob G.F., et al. Anxiolytic-like action of neuropeptide Y: mediation by Y1 receptors in amygdala, and dissociation from food intake effects. Neuropsychopharmacology 1993, 8:357-363.
53. Heinrichs S.C., De Souza E.B., Schulteis G., Lapsansky J.L., Grigoriadis D.E. Brain penetrance, receptor occupancy and antistress in vivo efficacy of a small molecule corticotropin releasing factor type I receptor selective antagonist. Neuropsychopharmacology 2002, 27:194-202. 10.1016/S0893-133X(02)00299-3.
54. Henry M., Fishman J.R., Youngner S.J. Propranolol and the prevention of post-traumatic stress disorder:is it wrong to erase the " sting" of bad memories?. The American Journal of Bioethics 2007, 7:12-20. 10.1080/15265160701518474.
55. Hertzberg M.A., Moore S.D., Feldman M.E., Beckham J.C. A preliminary study of bupropion sustained-release for smoking cessation in patients with chronic posttraumatic stress disorder. Journal of Clinical Psychopharmacology 2001, 21:94-98.
56. Hofmann S.G., Meuret A.E., Smits J.A.J., Simon N.M., Pollack M.H., Eisenmenger K., et al. Augmentation of exposure therapy with d-cycloserine for social anxiety disorder. Archives of General Psychiatry 2006, 63:298-304. 10.1001/archpsyc.63.3.298.
57. Hofmann S.G., Smits J.A.J., Asnaani A., Gutner C.A., Otto M.W. Cognitive enhancers for anxiety disorders. Pharmacology, Biochemistry, and Behavior 2011, 99:275-284. 10.1016/j.pbb.2010.11.020.
58. Holmes A., Quirk G.J. Pharmacological facilitation of fear extinction and the search for adjunct treatments for anxiety disorders--the case of yohimbine. Trends in Pharmacological Sciences 2010, 31:2-7. 10.1016/j.tips.2009.10.003.
59. Holmes A., Heilig M., Rupniak N.M.J., Steckler T., Griebel G. Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders. Trends in Pharmacological Sciences 2003, 24:580-588.
60. Insel T.R., Cuthbert B.N., Garvey M.A., Heinssen R.K., Pine D.S., Quinn K.J., et al. Research domain criteria (RDoC): toward a new classification framework for research on mental disorders. American Journal of Psychiatry 2010, 167:748-751.
61. Ipser J.C., Carey P., Dhansay Y., Fakier N., Seedat S., Stein D.J. Pharmacotherapy augmentation strategies in treatment-resistant anxiety disorders. Cochrane database of systematic reviews 2006, John Wiley & Sons, Ltd., Chichester, UK, Retrieved from. http://doi.wiley.com/10.1002/14651858.CD005473.pub2, The Cochrane Collaboration, J.C. Ipser (Eds.).
62. James I.M., Burgoyne W., Savage I.T. Effect of pindolol on stress-related disturbances of musical performance:preliminary communication. Journal of the Royal Society of Medicine 1983, 76:194-196.
63. Johansen P., Krebs T. How could MDMA (ecstasy) help anxiety disorders? A neurobiological rationale. Journal of Psychopharmacology 2009, 23:389-391. 10.1177/0269881109102787.
64. Kaizar E.E., Greenhouse J.B., Seltman H., Kelleher K. Do antidepressants cause suicidality in children? A Bayesian meta-analysis. Clinical Trials 2006, 3:73-98. 10.1191/1740774506cn139oa.
65. Katz R.J., DeVeaugh-Geiss J., Landau P. Clomipramine in obsessive-compulsive disorder. Biological Psychiatry 1990, 28:401-414. 10.1016/0006-3223(90)90408-T.
66. Klein D.F. Causal thinking for objective psychiatric diagnostic criteria. Causality and psychopathology:finding the determinants of disorders and their cures 2011, 321-337. Oxford University Press, New York. P.E. Shrout, K.M. Keyes, K. Ornstein (Eds.).
67. Komossa K., Depping A.M., Meyer M., Kissling W., Leucht S. Second-generation antipsychotics for obsessive compulsive disorder. Cochrane database of systematic reviews 2010, John Wiley & Sons, Ltd., Chichester, UK, Retrieved from: http://doi.wiley.com/10.1002/14651858.CD008141.pub2, The Cochrane Collaboration, K. Komossa (Eds.).
68. Kramer M.S., Cutler N., Feighner J., Shrivastava R., Carman J., Sramek J.J., et al. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 1998, 281:1640-1645.
69. Krishnan V., Nestler E.J. The molecular neurobiology of depression. Nature 2008, 455:894-902. 10.1038/nature07455.
70. Krystal J.H., Petrakis I.L., Mason G., Trevisan L., D'Souza D.C. N-methyl-d-aspartate glutamate receptors and alcoholism:reward, dependence, treatment, and vulnerability. Pharmacology and Therapeutics 2003, 99:79-94. 10.1016/S0163-7258(03)00054-8.
71. Krystal J.H., Rosenheck R.A., Cramer J.A., Vessicchio J.C., Jones K.M., Vertrees J.E., et al. Adjunctive risperidone treatment for antidepressant-resistant symptoms of chronic military service-related PTSD. Journal of the American Medical Association 2011, 306:493-502. 10.1001/jama.2011.1080.
72. Kuriyama K., Honma M., Koyama S., Kim Y. d-Cycloserine facilitates procedural learning but not declarative learning in healthy humans:a randomized controlled trial of the effect of d-cycloserine and valproic acid on overnight properties in the performance of non-emotional memory tasks. Neurobiology of Learning and Memory 2011, 95:505-509. 10.1016/j.nlm.2011.02.017.
73. Langton J.M., Richardson R. d-Cycloserine facilitates extinction the first time but not the second time:an examination of the role of NMDA across the course of repeated extinction sessions. Neuropsychopharmacology 2008, 33:3096-3102.
74. Lee J.L.C., Milton A.L., Everitt B.J. Reconsolidation and extinction of conditioned fear:inhibition and potentiation. The Journal of Neuroscience 2006, 26:10051-10056. 10.1523/JNEUROSCI.2466-06.2006.
75. Löw K., Crestani F., Keist R., Benke D., Brünig I., Benson J.A., et al. Molecular and neuronal substrate for the selective attenuation of anxiety. Science 2000, 290:131-134. 10.1126/science.290.5489.131.
76. Madaan V., Wilson D.R. Neuropeptides: relevance in treatment of depression and anxiety disorders. Drug News and Perspectives 2009, 22:319-325. 10.1358/dnp.2009.22.6.1395255.
77. Malberg J.E., Seiden L.S. Small changes in ambient temperature cause large changes in 3,4-methylenedioxymethamphetamine (MDMA)-induced serotonin neurotoxicity and core body temperature in the rat. The Journal of Neuroscience 1998, 18:5086-5094.
78. Marks D.M., Thanaseelan J., Pae C.-U. Innovations in clinical research design and conduct in psychiatry:shifting to pragmatic approaches. Psychiatry Investigation 2009, 6:1-6. 10.4306/pi.2009.6.1.1.
79. Marshall R.D., Beebe K.L., Oldham M., Zaninelli R. Efficacy and safety of paroxetine treatment for chronic PTSD: a fixed-dose, placebo-controlled study. American Journal of Psychiatry 2001, 158:1982-1988.
80. Mathew S.J., Keegan K., Smith L. Glutamate modulators as novel interventions for mood disorders. Revista Brasileira de Psiquiatria 2005, 27:243-248. 10.1590/S1516-44462005000300016.
81. Mathew S.J., Vythilingam M., Murrough J.W., Zarate C.A., Feder A., Luckenbaugh D.A., et al. A selective neurokinin-1 receptor antagonist in chronic PTSD: a randomized, double-blind, placebo-controlled, proof-of-concept trial. European Neuropsychopharmacology 2011, 21:221-229. 10.1016/j.euroneuro.2010.11.012.
82. Mavissakalian M.R. Imipramine vs. sertraline in panic disorder: 24-week treatment completers. Annals of Clinical Psychiatry 2003, 15:171-180.
83. McCann U.D., Szabo Z., Scheffel U., Dannals R.F., Ricaurte G.A. Positron emission tomographic evidence of toxic effect of MDMA (" Ecstasy") on brain serotonin neurons in human beings. Lancet 1998, 352:1433-1437.
84. McGaugh J.L. Memory: a century of consolidation. Science 2000, 287:248-251.
85. McGaugh J.L., Roozendaal B. Drug enhancement of memory consolidation:historical perspective and neurobiological implications. Psychopharmacology 2009, 202:3-14. 10.1007/s00213-008-1285-6.
86. Mechoulam R., Parker L.A., Gallily R. Cannabidiol: an overview of some pharmacological aspects. Journal of Clinical Pharmacology 2002, 42:11S-19S.
87. Milekic M.H., Alberini C.M. Temporally graded requirement for protein synthesis following memory reactivation. Neuron 2002, 36:521-525. 10.1016/S0896-6273(02)00976-5.
88. Miller G. Is pharma running out of brainy ideas?. Science 2010, 329:502-504. 10.1126/science.329.5991.502.
89. Möhler H. The GABA system in anxiety and depression and its potential for novel therapeutics. Neuropharmacology 2012, 62:42-53. 10.1016/j.neuropharm.2011.08.040.
90. Montgomery S.A., Sheehan D.V., Meoni P., Haudiquet V., Hackett D. Characterization of the longitudinal course of improvement in generalized anxiety disorder during long-term treatment with venlafaxine XR. Journal of Psychiatric Research 2002, 36:209-217. 10.1016/S0022-3956(02)00005-5.
91. Muehlbacher M., Nickel M.K., Nickel C., Kettler C., Lahmann C., Gil F.P., et al. Mirtazapine treatment of social phobia in women. Journal of Clinical Psychopharmacology 2005, 25:580-583. 10.1097/01.jcp.0000186871.04984.8d.
92. Mullins C.D., Shaya F.T., Meng F., Wang J., Bron M.S. Comparison of first refill rates among users of sertraline, paroxetine, and citalopram. Clinical Therapeutics 2006, 28:297-305.
93. Muravieva E.V., Alberini C.M. Limited efficacy of propranolol on the reconsolidation of fear memories. Learning and Memory 2010, 17:306-313. 10.1101/lm.1794710.
94. Nemeroff C.B. Anxiolytics: past, present, and future agents. Journal of Clinical Psychiatry 2003, 64:3-6.
95. Norberg M.M., Krystal J.H., Tolin D.F. A meta-analysis of d-cycloserine and the facilitation of fear extinction and exposure therapy. Biological Psychiatry 2008, 63:1118-1126. 10.1016/j.biopsych.2008.01.012.
96. Oetting A.I., Levy J.A., Weiss R.D., Murphy S.A. Statistical methodology for a SMART design in the development of adaptive treatment strategies. Causality and psychopathology:finding the determinants of disorders and their cures 2011, 179-205. Oxford University Press, New York. P.E. Shrout, K.M. Keyes, K. Ornstein (Eds.).
97. Otto M.W., Smits J.A.J., Reese H.E. Combined psychotherapy and pharmacotherapy for mood and anxiety disorders in adults:review and analysis. Clinical Psychology: Science and Practice 2005, 12:72-86.
98. Otto M.W., Basden S.L., McHugh R.K., Kantak K.M., Deckersbach T., Cather C., et al. Effects of d-cycloserine administration on weekly nonemotional memory tasks in healthy participants. Psychotherapy and Psychosomatics 2009, 78:49-54. 10.1159/000172620.
99. Otto M.W., McHugh R.K., Simon N.M., Farach F.J., Worthington J.J., Pollack M.H. Efficacy of CBT for benzodiazepine discontinuation in patients with panic disorder:further evaluation. Behaviour Research and Therapy 2010, 48:720-727. 10.1016/j.brat.2010.04.002.
100. Paul G.L. Behavior modification research:design and tactics. Behavior therapy:appraisal and status 1969, 29-62. McGraw-Hill, New York. C.M. Franks (Ed.).
101. Pitman R.K., Sanders K.M., Zusman R.M., Healy A.R., Cheema F., Lasko N.B., et al. Pilot study of secondary prevention of posttraumatic stress disorder with propranolol. Biological Psychiatry 2002, 51:189-192.
102. Pittenger C., Coric V., Banasr M., Bloch M., Krystal J.H., Sanacora G. Riluzole in the treatment of mood and anxiety disorders. CNS Drugs 2008, 22:761-786.
103. Pollack M.H., Mangano R., Entsuah R., Tzanis E., Simon N.M., Zhang Y. A randomized controlled trial of venlafaxine ER and paroxetine in the treatment of outpatients with panic disorder. Psychopharmacology 2007, 194:233-242. 10.1007/s00213-007-0821-0.
104. Pollack M.H., Kinrys G., Krystal A., McCall W.V., Roth T., Schaefer K., et al. Eszopiclone coadministered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder. Archives of General Psychiatry 2008, 65:551-562. 10.1001/archpsyc.65.5.551.
105. Pollack M.H., Otto M.W., Roy-Byrne P.P., Coplan J.D., Rothbaum B.O., Simon N.M., et al. Novel treatment approaches for refractory anxiety disorders. Focus 2008, 6:486-495.
106. Pollack M.H., Hoge E.A., Worthington J.J., Moshier S.J., Wechsler R.S., Brandes M., et al. Eszopiclone for the treatment of posttraumatic stress disorder and associated insomnia. Journal of Clinical Psychiatry 2011, 72:892-897. 10.4088/JCP.09m05607gry.
107. Powers M.B., Smits J.A.J., Otto M.W., Sanders C., Emmelkamp P.M.G. Facilitation of fear extinction in phobic participants with a novel cognitive enhancer:a randomized placebo controlled trial of yohimbine augmentation. Journal of Anxiety Disorders 2009, 23:350-356. 10.1016/j.janxdis.2009.01.001.
108. President's Council on Bioethics Beyond therapy:biotechnology and the pursuit of happiness 2003, Government Printing Office, Washington, DC.
109. Przybyslawski J., Roullet P., Sara S.J. Attenuation of emotional and nonemotional memories after their reactivation:role of beta adrenergic receptors. The Journal of Neuroscience 1999, 19:6623-6628.
110. Quirk G.J., Mueller D. Neural mechanisms of extinction learning and retrieval. Neuropsychopharmacology 2007, 33:56-72.
111. Rachman S. The determinants and treatment of simple phobias. Advances in Behaviour Research and Therapy 1990, 12:1-30. 10.1016/0146-6402(90)90005-B.
112. Ravindran L.N., Stein M.B. Pharmacotherapy of PTSD: premises, principles, and priorities. Brain Research 2009, 1293:24-39. 10.1016/j.brainres.2009.03.037.
113. Ravindran L.N., Stein M.B. The pharmacologic treatment of anxiety disorders. Journal of Clinical Psychiatry 2010, 71:839-854. 10.4088/JCP.10r06218blu.
114. Reneman L., Lavalaye J., Schmand B., de Wolff F.A., van den Brink W., den Heeten G.J., et al. Cortical serotonin transporter density and verbal memory in individuals who stopped using 3,4-methylenedioxymethamphetamine (MDMA or " ecstasy"): preliminary findings. Archives of General Psychiatry 2001, 58:901-906.
115. Ressler K.J., Rothbaum B.O., Tannenbaum L., Anderson P., Graap K., Zimand E., et al. Cognitive enhancers as adjuncts to psychotherapy:use of d-cycloserine in phobic individuals to facilitate extinction of fear. Archives of General Psychiatry 2004, 61:1136-1144. 10.1001/archpsyc.61.11.1136.
116. Rickels K., Downing R., Schweizer E., Hassman H. Antidepressants for the treatment of generalized anxiety disorder:a placebo-controlled comparison of imipramine, trazodone, and diazepam. Archives of General Psychiatry 1993, 50:884-895.
117. Rodriguez C.I., Kegeles L.S., Flood P., Simpson H.B. Rapid resolution of obsessions after an infusion of intravenous ketamine in a patient with treatment-resistant obsessive-compulsive disorder. The Journal of Clinical Psychiatry 2011, 72:567-569. 10.4088/JCP.10l06653.
118. Roesler R., Schröder N. Cognitive enhancers:focus on modulatory signaling influencing memory consolidation. Pharmacology, Biochemistry, and Behavior 2011, 99:155-163. 10.1016/j.pbb.2010.12.028.
119. Rojas J.C., Bruchey A.K., Gonzalez-Lima F. Neurometabolic mechanisms for memory enhancement and neuroprotection of methylene blue. Progress in Neurobiology 2012, 96:32-45. 10.1016/j.pneurobio.2011.10.007.
120. Rothbaum B.O., Davis M. Applying learning principles to the treatment of post-trauma reactions. Annals of the New York Academy of Sciences 2003, 1008:209-211.
121. Rudolph R.L., Fabre L.F., Feighner J.P., Rickels K., Entsuah R., Derivan A.T. A randomized, placebo-controlled, dose-response trial of venlafaxine hydrochloride in the treatment of major depression. Journal of Clinical Psychiatry 1998, 59:116-122.
122. Rush A.J. Limitations in efficacy of antidepressant monotherapy. The Journal of Clinical Psychiatry 2007, 68(Suppl. 10):8-10.
123. Sara S.J. Retrieval and reconsolidation:toward a neurobiology of remembering. Learning and Memory 2000, 7:73-84.
124. Schelling G., Roozendaal B., De Quervain D.J.-F. Can posttraumatic stress disorder be prevented with glucocorticoids?. Annals of the New York Academy of Sciences 2004, 1032:158-166. 10.1196/annals.1314.013.
125. Schmitt R., Gazalle F.K., Lima M.S., de Cunha Ã., Souza J., Kapczinski F. The efficacy of antidepressants for generalized anxiety disorder:a systematic review and meta-analysis. Revista Brasileira de Psiquiatria 2005, 27:18-24.
126. Schutters S.I.J., Van Megen H.J.G.M., Van Veen J.F., Denys D.A.J.P., Westenberg H.G.M. Mirtazapine in generalized social anxiety disorder:a randomized, double-blind, placebo-controlled study. International Clinical Psychopharmacology 2010, 25:302-304.
127. Siegmund A., Golfels F., Finck C., Halisch A., Raeth D., Plag J., et al. d-Cycloserine does not improve but might slightly speed up the outcome of in vivo exposure therapy in patients with severe agoraphobia and panic disorder in a randomized double blind clinical trial. Journal of Psychiatric Research 2011, 45:1042-1047. 10.1016/j.jpsychires.2011.01.020.
128. Simon N.M., Connor K.M., Lang A.J., Rauch S., Krulewicz S., LeBeau R.T., et al. Paroxetine CR augmentation for posttraumatic stress disorder refractory to prolonged exposure therapy. The Journal of Clinical Psychiatry 2008, 69:400-405.
129. Simon N.M., Otto M.W., Worthington J.J., Hoge E.A., Thompson E.H., LeBeau R.T., et al. Next-step strategies for panic disorder refractory to initial pharmacotherapy. Journal of Clinical Psychiatry 2009, 70:1563-1570. 10.4088/JCP.08m04485blu.
130. Snyder J.S., Soumier A., Brewer M., Pickel J., Cameron H.A. Adult hippocampal neurogenesis buffers stress responses and depressive behaviour. Nature 2011, 476:458-461. 10.1038/nature10287.
131. Stein D.J., Baldwin D.S., Baldinetti F., Mandel F. Efficacy of pregabalin in depressive symptoms associated with generalized anxiety disorder:a pooled analysis of 6 studies. European Neuropsychopharmacology 2008, 18:422-430. 10.1016/j.euroneuro.2008.01.004.
132. Strange B.A. An emotion-induced retrograde amnesia in humans is amygdala- and adrenergic-dependent. Proceedings of the National Academy of Sciences of the United States of America 2003, 100:13626-13631. 10.1073/pnas.1635116100.
133. Tam S.W., Worcel M., Wyllie M. Yohimbine: a clinical review. Pharmacology and Therapeutics 2001, 91:215-243. 10.1016/S0163-7258(01)00156-5.
134. Tancer M., Johanson C.-E. Reinforcing, subjective, and physiological effects of MDMA in humans: a comparison withd-amphetamine and mCPP. Drug and Alcohol Dependence 2003, 72:33-44.
135. Tedeschini E., Fava M., Papakostas G.I. Placebo-controlled, antidepressant clinical trials cannot be shortened to less than 4 weeks' duration. The Journal of Clinical Psychiatry 2011, 72:98-118. 10.4088/JCP.09m05725blu.
136. Thase M.E., Friedman E.S., Biggs M.M., Wisniewski S.R., Trivedi M.H., Luther J.F., et al. Cognitive therapy versus medication in augmentation and switch strategies as second-step treatments:a STAR D report. The American Journal of Psychiatry 2007, 164:739-752. 10.1176/appi.ajp.164.5.739.
137. Urschel H.C., Hanselka L.L., Baron M. A controlled trial of flumazenil and gabapentin for initial treatment of methylamphetamine dependence. Journal of Psychopharmacology 2011, 25:254-262. 10.1177/0269881109349837.
138. Vaiva G., Ducrocq F., Jezequel K., Averland B., Lestavel P., Brunet A., et al. Immediate treatment with propranolol decreases posttraumatic stress disorder two months after trauma. Biological Psychiatry 2003, 54:947-949.
139. Van Ameringen M., Mancini M., Oakman C., Walker J., Kjernisted J., Chokka P., et al. Nefazodone in the treatment of generalized social phobia:a randomized, placebo-controlled trial. Journal of Clinical Psychiatry 2007, 68:288-295.
140. Vollenweider F.X., Kometer M. The neurobiology of psychedelic drugs:implications for the treatment of mood disorders. Nature Reviews: Neuroscience 2010, 11:642-651. 10.1038/nrn2884.
141. Vollenweider F.X., Gamma A., Liechti M., Huber T. Psychological and cardiovascular effects and short-term sequelae of MDMA (" ecstasy") in MDMA-naïve healthy volunteers. Neuropsychopharmacology 1998, 19:241-251. 10.1016/S0893-133X(98)00013-X.
142. Vollenweider F.X., Liechti M.E., Gamma A., Greer G., Geyer M. Acute psychological and neurophysiological effects of MDMA in humans. Journal of Psychoactive Drugs 2002, 34:171-184.
143. Wang P.S., Lane M., Olfson M., Pincus H.A., Wells K.B., Kessler R.C. Twelve-month use of mental health services in the United States: results from the National Comorbidity Survey Replication. Archives of General Psychiatry 2005, 62:629-640.
144. Warden D., Rush A.J., Carmody T.J., Kashner T.M., Biggs M.M., Crismon M.L., et al. Predictors of attrition during one year of depression treatment:a roadmap to personalized intervention. Journal of Psychiatric Practice 2009, 15:113-124.
145. Watanabe N., Churchill R., Furukawa T. Combination of psychotherapy and benzodiazepines versus either therapy alone for panic disorder:a systematic review. BMC Psychiatry 2007, 7:18. 10.1186/1471-244X-7-18.
146. Webb A.J.S., Fischer U., Rothwell P.M. Effects of β-blocker selectivity on blood pressure variability and stroke:a systematic review. Neurology 2011, 77:731-737. 10.1212/WNL.0b013e31822b007a.
147. Westra H.A., Stewart S.H., Conrad B.E. Naturalistic manner of benzodiazepine use and cognitive behavioral therapy outcome in panic disorder with agoraphobia. Journal of Anxiety Disorders 2002, 16:233-246.
148. Zakzanis K.K., Young D.A. Memory impairment in abstinent MDMA (" Ecstasy") users:a longitudinal investigation. Neurology 2001, 56:966-969.
149. Zarate C.A., Singh J.B., Carlson P.J., Brutsche N.E., Ameli R., Luckenbaugh D.A., et al. A randomized trial of an N-methyl-d-aspartate antagonist in treatment-resistant major depression. Archives of General Psychiatry 2006, 63:856-864. 10.1001/archpsyc.63.8.856.
150. Zobel A.W., Nickel T., Künzel H.E., Ackl N., Sonntag A., Ising M., et al. Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression:the first 20 patients treated. Journal of Psychiatric Research 2000, 34:171-181.
151. Zuardi A.W. Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action. Revista Brasileira de Psiquiatria 2008, 30:271-280.
152. Zwanzger P., Diemer J., Jabs B. Comparison of combined psycho- and pharmacotherapy with monotherapy in anxiety disorders:controversial viewpoints and clinical perspectives. Journal of Neural Transmission 2008, 116:759-765. 10.1007/s00702-008-0116-6.